EXHIBIT 99.1 Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update HAMPTON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2025 and provided a corporate update. "In the second quarter of 2025, data from our now completed Phase 2 study in chronic spontaneous urticaria were presented that we believe clearly show that barzolvolimab is best in disease and achieves the goal of tr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38221 Ecovyst Inc. (State or other jurisdiction of incorporation or organization) 600 Lee Road, Suite 200 Wayne, Pennsylvania 19 ...

Press Release For Immediate Release Reiterates 4Q 2025 launch timing for 5G Increases 2025 Financial Guidance, which includes current impact of global tariffs BROOMFIELD, Colo. - August 7, 2025 – Gogo Inc. (NASDAQ: GOGO) ("Gogo" or the "Company"), a leading global provider of broadband connectivity services for the business and military/government mobility aviation markets, today announced its financial results for the quarter ended June 30, 2025. Second quarter financial results for Gogo include the impact ...

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Consolidated Financial Statements](index=4&type=section&id=Item%201.%20Consolidated%20Financial%20Statements) This section presents the unaudited consolidated financial statements, including assets, operations, cash flows, and investment schedules, for Q2 2025 [Consolidated Statements of Assets and Liabilities](index=4&type=section&id=Consolidated%20Statements%20of%20Assets%20and%20Liabilities) Total assets decreased to **$1.04 billion** by June 30, 2025, reducing net assets to **$498.9 million** and NAV per share to **$13.66** Consolidated Statements of Assets and Liabilities (in thousands) | Metric | June 30, 2025 (Unaudited) | December 31, 2024 | | :--- | :--- | :--- | | Total investments at fair value | $1,024,951 | $1,076,840 | | Total assets | $1,041,257 | $1,091,355 | | Total debt, less unamortized deferred financing costs | $515,948 | $552,332 | | Total liabilities | $542,383 | $576,486 | | Total net assets | $498,874 | $514,869 | | Net asset value per share | $13.66 | $13.79 | [Consolidated Statements of Operations](index=5&type=section&id=Consolidated%20Statements%20of%20Operations) Q2 2025 total investment income was **$35.1 million**, with net investment income at **$13.9 million**, and a net increase in net assets of **$16.8 million** Financial Performance Summary (in thousands, except per share data) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Total Investment Income | $35,147 | $34,193 | $70,545 | $74,202 | | Net Investment Income | $13,948 | $14,591 | $29,547 | $33,255 | | Net Realized and Unrealized Gain (Loss) | $2,849 | $(6,300) | $(10,884) | $(12,917) | | **Net Increase (Decrease) in Net Assets** | **$16,797** | **$8,291** | **$18,663** | **$20,338** | | Net Investment Income per Share | $0.38 | $0.37 | $0.79 | $0.84 | | Net Increase (Decrease) in Net Assets per Share | $0.45 | $0.21 | $0.50 | $0.51 | [Consolidated Statements of Changes in Net Assets](index=6&type=section&id=Consolidated%20Statements%20of%20Changes%20in%20Net%20Assets) Net assets decreased by **$16.0 million** for the six months ended June 30, 2025, primarily due to distributions and stock repurchases Reconciliation of Net Assets for the Six Months Ended June 30, 2025 (in thousands) | Description | Amount | | :--- | :--- | | Balances at December 31, 2024 | $514,869 | | Net increase in net assets from operations | $18,663 | | Repurchase of common stock | $(8,141) | | Dividends paid to stockholders | $(26,517) | | **Balances at June 30, 2025** | **$498,874** | [Consolidated Statements of Cash Flows](index=7&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Net cash from operating activities significantly increased to **$73.3 million** for H1 2025, with **$6.0 million** cash at period-end Cash Flow Summary for the Six Months Ended June 30 (in thousands) | Cash Flow Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $73,265 | $29,953 | | Net cash (used in) provided by financing activities | $(73,058) | $(24,113) | | Net increase (decrease) in cash and cash equivalents | $209 | $5,840 | | **Cash and cash equivalents at end of period** | **$5,960** | **$8,810** | [Consolidated Schedule of Investments](index=8&type=section&id=Consolidated%20Schedule%20of%20Investments) The investment portfolio totaled **$1.025 billion** as of June 30, 2025, primarily in debt investments (**93.9%**), with top concentrations in Application Software Portfolio Composition by Investment Type (June 30, 2025) | Investment Type | Cost ($k) | Fair Value ($k) | % of Total Portfolio | | :--- | :--- | :--- | :--- | | Senior Secured Loans | 955,354 | 941,705 | 91.88% | | Second Lien Loans | 20,902 | 20,778 | 2.03% | | Preferred Stock/Units | 51,920 | 39,549 | 3.86% | | Warrants | 23,804 | 14,500 | 1.41% | | Other | 14,084 | 8,419 | 0.82% | | **Total** | **1,066,064** | **1,024,951** | **100.00%** | Top 5 Industry Concentrations by Fair Value (June 30, 2025) | Industry | Investments at Fair Value ($k) | Percentage of Net Assets | | :--- | :--- | :--- | | Application Software | $225,083 | 45.12% | | Commercial & Professional Services | $177,181 | 35.51% | | Health Care Equipment & Services | $145,164 | 29.10% | | Systems Software | $133,628 | 26.79% | | Technology Hardware & Equipment | $86,645 | 17.37% | [Notes to Consolidated Financial Statements](index=24&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) This section details accounting policies, fair value measurement, related party agreements, debt facilities, and tax status as a RIC [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=67&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial performance, portfolio activity, and liquidity, highlighting stable credit quality and strong liquidity with **$297.0 million** available - For the six months ended June 30, 2025, the company funded **$54.0 million** in new and existing portfolio companies and received **$107.9 million** in sales and repayments[229](index=229&type=chunk) - The dollar-weighted annualized yield on the debt investment portfolio was **15.4%** for Q2 2025, compared to **15.1%** for Q2 2024[227](index=227&type=chunk) - As of June 30, 2025, the company had **$297.0 million** in available liquidity, including cash and availability under its Credit Facility, and an asset coverage ratio of **195%**[263](index=263&type=chunk)[264](index=264&type=chunk) [Portfolio Composition and Investment Activity](index=70&type=section&id=Portfolio%20Composition%20and%20Investment%20Activity) The **$1.025 billion** investment portfolio, primarily senior secured loans, saw **$54.0 million** funded and **$107.9 million** from repayments in H1 2025 Investment Portfolio Reconciliation (in thousands) | | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Beginning investment portfolio | $1,076,840 | $1,067,009 | | Purchases of investments | $54,039 | $100,025 | | Sales and repayments of investments | $(107,873) | $(61,507) | | Net realized/unrealized & other | $(9,455) | $(12,036) | | **Ending investment portfolio** | **$1,024,951** | **$1,063,324** | [Asset Quality](index=72&type=section&id=Asset%20Quality) Debt portfolio credit quality remained strong, with **93.9%** in top categories and only **one investment** on non-accrual status as of June 30, 2025 Debt Investment Rating Distribution by Fair Value | Investment Rating | June 30, 2025 (% of Portfolio) | December 31, 2024 (% of Portfolio) | | :--- | :--- | :--- | | 1 (Strong Performance) | 2.18% | 2.53% | | 2 (Acceptable Performance) | 66.05% | 62.39% | | 3 (Below Plan, Monitored) | 21.83% | 21.50% | | 4 (Materially Below Plan) | 3.62% | 3.17% | | 5 (Going Concern Issues) | 0.23% | 0.52% | - As of June 30, 2025, only **one investment**, Mingle Healthcare Solutions, Inc., was on non-accrual status, with a fair value of **$2.4 million**. This is an improvement from **two investments** with a fair value of **$5.6 million** at the end of 2024[233](index=233&type=chunk) [Results of Operations](index=73&type=section&id=Results%20of%20Operations) Q2 2025 net investment income was **$13.9 million**, impacted by higher expenses, with a net unrealized gain of **$4.4 million** Comparison of Results of Operations (in thousands) | | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :--- | :--- | :--- | | Total investment income | $35,147 | $34,193 | | Total operating expenses | $21,199 | $19,602 | | **Net investment income** | **$13,948** | **$14,591** | | Net realized gain (loss) | $(1,512) | $0 | | Net change in unrealized gain (loss) | $4,361 | $(6,300) | | **Net increase in net assets** | **$16,797** | **$8,291** | [Financial Condition, Liquidity, Capital Resources and Obligations](index=78&type=section&id=Financial%20Condition%2C%20Liquidity%2C%20Capital%20Resources%20and%20Obligations) The company maintains robust liquidity with **$297.0 million** available and a **195%** asset coverage ratio, continuing its capital return strategy - As of June 30, 2025, the company had **$297.0 million** in available liquidity, including **$6.0 million** in cash and **$291.0 million** available under its Credit Facility[263](index=263&type=chunk) - The asset coverage ratio was **195%** as of June 30, 2025, exceeding the regulatory requirement of **150%**[264](index=264&type=chunk) - On May 7, 2025, the Board approved a new **$25.0 million** share repurchase program. Through June 30, 2025, the company repurchased **815,408 shares** for **$8.1 million** under this program[275](index=275&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=82&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company faces valuation and interest rate risks, with **96.7%** of performing debt at variable rates, sensitive to rate changes - The company's investments are primarily **illiquid Level 3 investments** and valued in good faith by the Board of Directors, creating **valuation risk** as these values may differ significantly from those in a ready market[284](index=284&type=chunk) - As of June 30, 2025, **96.7%** of the company's performing debt portfolio bore interest at **variable rates**, primarily tied to SOFR and Prime rates[286](index=286&type=chunk) Annualized Interest Rate Sensitivity Analysis | Scenario | Maximum Impact on Investment Income | | :--- | :--- | | 200 basis point increase | +$17.3 million | | 200 basis point decrease | -$10.9 million | [Controls and Procedures](index=84&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were **effective**, with no material changes to internal control over financial reporting - The CEO and CFO concluded that the company's disclosure controls and procedures are **effective** in timely alerting them to material information required for SEC reporting[293](index=293&type=chunk) - **No changes occurred** during the quarter that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[294](index=294&type=chunk) [PART II. OTHER INFORMATION](index=85&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=85&type=section&id=Item%201.%20Legal%20Proceedings) The company and its adviser are **not currently subject to any material legal proceedings** - The Company and its adviser, RGC, are **not currently subject to any material legal proceedings**[297](index=297&type=chunk) [Risk Factors](index=85&type=section&id=Item%201A.%20Risk%20Factors) **No material changes** to previously disclosed risk factors have occurred - **No material changes** to the risk factors discussed in the Annual Report on Form 10-K for the year ended December 31, 2024, have occurred during the period ended June 30, 2025[299](index=299&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=85&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company repurchased **815,408 shares** under its Fourth Repurchase Program, with **$16.9 million** remaining for future repurchases - During the three and six months ended June 30, 2025, the company repurchased **815,408 shares** under its Fourth Repurchase Program[302](index=302&type=chunk) - As of June 30, 2025, approximately **$16.9 million** remained available for share repurchases under the Fourth Repurchase Program[302](index=302&type=chunk) [Defaults Upon Senior Securities](index=85&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) **No defaults** upon senior securities were reported during the period - **None**[303](index=303&type=chunk) [Other Information](index=85&type=section&id=Item%205.%20Other%20Information) No other material information was required, and **no director or officer** entered into Rule 10b5-1 trading plans - For the period covered by the report, **no director or officer** of the Company has entered into any Rule 10b5-1 trading plans or other non-Rule 10b5-1 trading arrangements[306](index=306&type=chunk) [Exhibits](index=87&type=section&id=Item%206.%20Exhibits) Exhibits include CEO and CFO certifications and Inline XBRL documents - Exhibits filed include CEO and CFO certifications pursuant to Rule 13a-14 and Section 906 of the Sarbanes-Oxley Act, along with Inline XBRL documents[307](index=307&type=chunk) [Signatures](index=88&type=section&id=SIGNATURES) The report was **duly signed and authorized** on August 7, 2025, by the CEO and CFO - The report was **duly signed and authorized** on August 7, 2025, by R. David Spreng, President and Chief Executive Officer, and Thomas B. Raterman, Chief Financial Officer[309](index=309&type=chunk)[311](index=311&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 For the transition period from to Commission File Number: 001-42192 COVENANT LOGISTICS GROUP, INC. (Exact name of registrant as specified in its charter) Nevada 88-0320154 (State or other ju ...

[Report Overview](index=1&type=section&id=Report%20Overview) [Strategic and Financial Highlights](index=1&type=section&id=Strategic%20and%20Financial%20Highlights) Rocket Pharmaceuticals announced a strategic pivot to prioritize its AAV cardiovascular gene therapy platform, alongside a significant organizational restructuring aimed at reducing costs. The company reported a cash position of $271.5 million, providing an operational runway into the second quarter of 2027, and appointed Chris Stevens as the new Chief Operating Officer - Strategic focus has been refined to prioritize the development of the AAV cardiovascular gene therapy platform, specifically RP-A501 (Danon disease), RP-A601 (PKP2-ACM), and RP-A701 (BAG3-DCM)[1](index=1&type=chunk) - An organizational restructuring is underway, expected to reduce headcount by approximately **30%** and lower the 12-month cash burn by nearly **25%**[1](index=1&type=chunk)[8](index=8&type=chunk) - The company reported cash, cash equivalents, and investments of approximately **$271.5 million**, which is expected to fund operations into the second quarter of **2027**[1](index=1&type=chunk)[9](index=9&type=chunk) - Chris Stevens has been appointed as the new Chief Operating Officer[1](index=1&type=chunk)[6](index=6&type=chunk) [CEO's Statement](index=1&type=section&id=CEO%27s%20Statement) The CEO, Gaurav Shah, M.D., highlighted the second quarter of 2025 as an inflection point where the company sharpened its focus on its high-value AAV cardiovascular platform. He noted that this strategic shift, which includes pausing investments in the Fanconi Anemia (FA) and Pyruvate Kinase Deficiency (PKD) programs, strengthens the company's financial foundation and positions it as a leader in gene therapies for inherited cardiomyopathies - The company is fortifying its path to sustained value creation by focusing on programs with the highest value, conserving cash, and driving an efficient organization[3](index=3&type=chunk) - Rocket is pausing additional investments in its Fanconi Anemia (FA; RP-L102) and Pyruvate Kinase Deficiency (PKD; RP-L301) programs and is exploring strategic alternatives to advance them externally[3](index=3&type=chunk)[8](index=8&type=chunk) - The CEO expressed confidence that the recent reorganization ensures the company is appropriately resourced to execute on near-term milestones with nearly **two years of capital**[3](index=3&type=chunk) [Recent Progress and Updates](index=2&type=section&id=Recent%20Progress%20and%20Updates) [Pipeline Updates](index=2&type=section&id=Pipeline%20Updates) The company provided key updates on its clinical pipeline. The Phase 2 study for RP-A501 (Danon disease) was placed on clinical hold by the FDA following a serious adverse event. In contrast, RP-A601 (PKP2-ACM) and RP-A701 (BAG3-DCM) received positive regulatory designations (RMAT and Fast Track, respectively), advancing them toward pivotal trials and clinical entry. The FDA review for KRESLADI™ (LAD-I) is ongoing, with a BLA submission expected by year-end 2025 [RP-A501 (Danon Disease)](index=2&type=section&id=RP-A501%20(Danon%20Disease)) The Phase 2 pivotal study for RP-A501 was placed on clinical hold by the FDA following a patient death, prompting a root cause analysis - The Phase 2 pivotal study for RP-A501 is on clinical hold by the FDA as of May 23, **2025**, following a Serious Adverse Event (SAE) that unfortunately led to a patient's death[4](index=4&type=chunk) - A root cause analysis is underway, focusing on the recent addition of a C3 inhibitor to the pre-treatment regimen[4](index=4&type=chunk) [RP-A601 (PKP2-ACM)](index=2&type=section&id=RP-A601%20(PKP2-ACM)) RP-A601 received FDA Regenerative Medicine Advanced Therapy (RMAT) designation, with the company engaging the FDA on a potential pivotal trial design following encouraging Phase 1 data - Received FDA Regenerative Medicine Advanced Therapy (RMAT) designation in July **2025**[1](index=1&type=chunk)[4](index=4&type=chunk) - Following encouraging initial Phase 1 data presented at ASGCT, Rocket is actively engaging with the FDA on a potential pivotal trial design[1](index=1&type=chunk)[4](index=4&type=chunk) [RP-A701 (BAG3-DCM)](index=2&type=section&id=RP-A701%20(BAG3-DCM)) The IND application for RP-A701 was cleared by the FDA, and the program received Fast Track designation, with Phase 1 trial start-up activities now underway - The Investigational New Drug (IND) application was cleared by the FDA in June **2025**[4](index=4&type=chunk) - RP-A701 was granted FDA Fast Track designation, and Phase 1 trial start-up activities are now underway[1](index=1&type=chunk)[4](index=4&type=chunk) [KRESLADI™ (LAD-I)](index=2&type=section&id=KRESLADI%E2%84%A2%20(LAD-I)) The FDA is reviewing additional CMC information for KRESLADI™, with the company expecting to submit the complete BLA to resolve the Complete Response Letter by year-end 2025 - The FDA is conducting a review of limited additional Chemistry Manufacturing and Controls (CMC) information for KRESLADI™[4](index=4&type=chunk) - The company anticipates submitting the complete Biologics License Application (BLA) to resolve the Complete Response Letter before the end of **2025**[4](index=4&type=chunk) [Corporate and Operational Updates](index=3&type=section&id=Corporate%20and%20Operational%20Updates) Rocket has executed a strategic corporate restructuring, reducing its workforce by approximately 30% to align with its prioritized focus on the AAV cardiovascular platform. This move is expected to cut operating expenses by nearly 25% over the next year. As part of this realignment, the company has paused further investment in its Fanconi Anemia and Pyruvate Kinase Deficiency programs. Additionally, Chris Stevens was appointed as the new Chief Operating Officer - Implemented a workforce reduction of approximately **30%** across all functions to align with the pipeline prioritization plan[8](index=8&type=chunk) - The restructuring and other cost-saving measures are expected to reduce operating expenses by nearly **25%** over the next **12 months**[8](index=8&type=chunk) - As part of the realignment, the company is pausing additional investments in its Fanconi Anemia (FA) and Pyruvate Kinase Deficiency (PKD) programs[8](index=8&type=chunk) - Appointed Chris Stevens, a seasoned executive with **25 years of experience** from Spark Therapeutics, as Chief Operating Officer[6](index=6&type=chunk) [Second Quarter 2025 Financial Results](index=3&type=section&id=Second%20Quarter%202025%20Financial%20Results) [Key Financial Metrics](index=3&type=section&id=Key%20Financial%20Metrics) For the second quarter of 2025, Rocket Pharmaceuticals reported a net loss of $68.9 million, or $0.62 per share, a slight improvement from the $69.6 million net loss in Q2 2024. The company reduced both R&D and G&A expenses year-over-year and ended the quarter with a solid cash position of $271.5 million Key Financial Metrics (in millions) | Financial Metric | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | Cash, Cash Equivalents & Investments | $271.5M | N/A | - | | R&D Expenses | $42.7M | $46.3M | ($3.6M) | | G&A Expenses | $25.0M | $27.4M | ($2.4M) | | Net Loss | ($68.9M) | ($69.6M) | $0.7M | | Net Loss Per Share | ($0.62) | ($0.74) | $0.12 | - The decrease in R&D expenses was primarily driven by lower costs for manufacturing, direct materials, and professional fees[9](index=9&type=chunk) - The decrease in G&A expenses was mainly due to reduced commercial preparation and compensation-related expenses[15](index=15&type=chunk) [Restructuring Expenses and Financial Guidance](index=4&type=section&id=Restructuring%20Expenses%20and%20Financial%20Guidance) The company incurred approximately $3.5 million in restructuring and related charges during the first half of 2025. Management expects its current cash, cash equivalents, and investments of $271.5 million will be sufficient to fund operations into the second quarter of 2027 - Approximately **$3.5 million** in restructuring and related charges were incurred in the first half of **2025**[10](index=10&type=chunk) - The company's cash runway is expected to extend into the second quarter of **2027**, excluding any potential proceeds from a Priority Review Voucher[9](index=9&type=chunk) [Consolidated Financial Statements](index=6&type=section&id=Consolidated%20Financial%20Statements) The consolidated statements of operations detail the company's financial performance for the three and six months ending June 30, 2025, showing a reduction in total operating expenses compared to the prior year. The balance sheet reflects total assets of $421.0 million and total stockholders' equity of $354.2 million as of June 30, 2025 Consolidated Statements of Operations (in thousands) | Statement of Operations | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :--- | :--- | :--- | | Research and development | $42,658 | $46,345 | | General and administrative | $25,020 | $27,367 | | Restructuring | $3,471 | $0 | | **Total operating expenses** | **$71,149** | **$73,712** | | **Loss from operations** | **($71,149)** | **($73,712)** | | **Net loss** | **($68,919)** | **($69,646)** | | **Net loss per share** | **($0.62)** | **($0.74)** | Consolidated Balance Sheets (in thousands) | Balance Sheet | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash, cash equivalents, and investments | $271,494 | $372,336 | | Total assets | $420,979 | $527,700 | | Total liabilities | $66,768 | $64,466 | | Total stockholders' equity | $354,211 | $463,234 | [Corporate Information](index=4&type=section&id=Corporate%20Information) [About Rocket Pharmaceuticals, Inc.](index=4&type=section&id=About%20Rocket%20Pharmaceuticals%2C%20Inc.) Rocket Pharmaceuticals is a late-stage biotechnology company developing a pipeline of genetic therapies for rare and complex disorders. The company utilizes a multi-platform approach, with an adeno-associated viral (AAV) vector-based portfolio for cardiovascular diseases and a lentiviral (LV) vector-based portfolio for hematology disorders - The company's AAV cardiovascular portfolio includes late-stage programs for Danon Disease and early-stage programs for PKP2-arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy[12](index=12&type=chunk) - The LV hematology portfolio consists of late-stage programs for Leukocyte Adhesion Deficiency-I (LAD-I), Fanconi Anemia (FA), and Pyruvate Kinase Deficiency (PKD)[13](index=13&type=chunk) [Forward-Looking Statements](index=5&type=section&id=Forward-Looking%20Statements) This section serves as a cautionary notice to investors, stating that the press release contains forward-looking statements that are subject to significant risks and uncertainties. These statements, which are not guarantees of future performance, pertain to the company's plans, clinical trial timings, regulatory outcomes, and financial projections. Readers are advised not to place undue reliance on them - The press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of **1995**[16](index=16&type=chunk) - These statements involve risks and uncertainties that could cause actual results to differ materially from expectations, including the ability to realize benefits from restructuring, trial outcomes, and regulatory decisions[16](index=16&type=chunk)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-36271 WATERSTONE FINANCIAL, INC. (Exact name of registrant as specified in its charter) Maryland 90-1026709 (State or other jurisdiction of incorporation or ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ______________ Commission file number: 001-33216 (Registrant's telephone number, including area code) N/A (Former name or former address a ...

For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to____________ Commission file number: 001-11015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) 1401 17th Street, Suite 1400 Denver, Colorado ...

Net income decreased to $20.8 million in Q2 2025 compared to $23.9 million for Q2 2024. The decrease was primarily due to the change in foreign exchange gain and loss. Q2 2025 net income margin was 23.7% compared to 27.3% for Q2 2024. (1) (1) Earnings per diluted share decreased to $1.07 or by 13.7% in Q2 2025 compared to $1.24 for Q2 2024. The decrease was primarily due to the item discussed above. (1) Adjusted EBITDA for Q2 2025 of $48.1 million decreased compared to Q2 2024 of $49.1 million primarily dri ...